Week in Review: RemeGen Out-Licenses Rights for HER2 ADC to Seagen in $2.6 Billion Deal

Deals and Financings   Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal; XtalPi, a US-China AI-based drug discovery company, completed a $400 million Series D financing at an estimated valuation of $2 billion; Shanghai 's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers;   COVID-19 Pandemic   Sorrento Therapeutics of San Diego and Suzhou signed a binding term sheet to license Dyadic's C1-cell protein platform including a COVID-19 vaccine; Advaccine Biopharma Suzhou will conduct China trials of Sinovac's approved COVID-19 vaccine combined with Innovio's DNA COVID-19 vaccine candidate; Trials and Approvals Suzhou Innovent Bio reported its PCSK-9 inhibitor mAb met its primary endpoint in a Phase III trial in  China  patients with genetic hypercholesterolemia; PhaseBio Pharma) and SFJ Pharma announced their partnered drug, a reversal agent for antiplatelets, was approved to start a China Phase III trial; Hangzhou Lynk Pharma started a US Phase I trial of its novel triple-kinase inhibitor in patients with myelofibrosis; Shanghai Belief Biomed was approved to start  China  trials of its IV infusion gene therapy for Hemophilia B; Junshi Biosciences of Shanghai and its  US  partner Coherus Bio reported their PD-1 candidate was granted Breakthrough Therapy Status in the  US .  Stock Symbols: (HK: 9995) (NSDQ: SGEN) (NSDQ/AIM: HCM; HKEX: 13) (NSDQ: SRNE) (NSDQ: INO) (HK: 01801) (NSDQ: PHAS) (HK: 1877; SHA: 688180) (NSDQ: CHRS) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.